Vimarsana
Biggest News Aggregation in the World

Page 32 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

FDA Grants Talquetamab Accelerated Approval for R/R Multiple Myeloma - Vimarsana News

FDA Grants Talquetamab Accelerated Approval for R/R Multiple Myeloma

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Source: ajmc.com
Dostarlimab/Chemo Approval Changes Treatment Paradigm for dMMR/MSI-H Advanced or Recurrent Endometrial Cancer - Vimarsana News

Dostarlimab/Chemo Approval Changes Treatment Paradigm for dMMR/MSI-H Advanced or Recurrent Endometrial Cancer

Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market - Vimarsana News

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market

/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration...

U.S. FDA Accepts Astellas' sNDA for CRESEMBA® (isavuconazonium sulfate) in Children - Vimarsana News

U.S. FDA Accepts Astellas' sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

/PRNewswire/ -- Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") announced that the U.S. Food and Drug Administration (FDA) has accepted the...

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma - Vimarsana News

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...